Argus raised the firm’s price target on Colgate-Palmolive to $107 from $97 and keeps a Buy rating on the shares. The analyst cites the company’s recent Q1 earnings beat while noting that the firm has a favorable view of its products with natural ingredients and of its new pet foods for younger pets and for older pets with kidney problems. Colgate-Palmolive has also met or exceeded its long-term target of 3%-5% organic sales growth for four consecutive years, the firm tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CL:
- VDC: Strong and Steady Consumer Staples ETF
- XLP ETF: Invest in Consumer Staples Stocks with Durable Demand
- Colgate-Palmolive price target raised to $100 from $96 at Bernstein
- Colgate-Palmolive price target raised to $85 from $84 at Barclays
- Colgate-Palmolive price target raised to $95 from $88 at RBC Capital
